Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

Taispeáin leaganacha eile (1)

Background For women with oestrogen receptor (ER)-positive early breast cancer, treatment with tamoxifen for 5 years substantially reduces the breast cancer mortality rate throughout the first 15 years after diagnosis. We aimed to assess the further effects of continuing tamoxifen to 10 years instea...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Davies, C, Pan, H, Gray, R, Collins, R, Delmestri, A, Wang, Y, Peto, R, Godwin, J, Arriagada, R, Raina, V, Abraham, M, Medeiros Alencar, V, Badran, A, Khaled, H, Bonfill, X, Tort, S, Urrútia, G, Bradbury, J, Davis, SR, Clarke, M, Forbes, J, Haddad, P, Hou, M, Inbar, M, Kielanowska, J
Formáid:	Journal article
Foilsithe / Cruthaithe:	2013

Míreanna comhchosúla

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
de réir: Davies, C, et al.
Foilsithe / Cruthaithe: (2013)

Five years of tamoxifen--or more?
de réir: Peto, R
Foilsithe / Cruthaithe: (1996)

Repurposing the Selective Oestrogen Receptor Modulator Tamoxifen for the Treatment of Duchenne Muscular Dystrophy
de réir: Elinam Gayi, et al.
Foilsithe / Cruthaithe: (2018-04-01)

10 vs 5 years of adjuvant tamoxifen: exclusion of 1/402 centres in ATLAS
de réir: Davies, C, et al.
Foilsithe / Cruthaithe: (2017)

Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer.
de réir: Andrew Stone, et al.
Foilsithe / Cruthaithe: (2012-01-01)

Aromatase Inhibitors (AIs) Versus Not (Placebo/Observation) as Late Extended Adjuvant Therapy for Postmenopausal Women with Early Stage Breast Cancer (BC): Overviews of Randomized Trials of AIs after similar to 5 Years of Tamoxifen
de réir: Goss, P, et al.
Foilsithe / Cruthaithe: (2009)

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen
de réir: Dowsett, M, et al.
Foilsithe / Cruthaithe: (2009)

20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years
de réir: Pan, H, et al.
Foilsithe / Cruthaithe: (2017)

Structural aspects of agonism and antagonism in the oestrogen receptor.
de réir: Pike, A, et al.
Foilsithe / Cruthaithe: (2000)

Overall and subgroup findings of the aTTom trial: A randomised comparison of continuing adjuvant tamoxifen to 10 years compared to stopping after 5 years in 6953 women with ER positive or ER untested early breast cancer
de réir: Rea, D, et al.
Foilsithe / Cruthaithe: (2013)

Variation in use of adjuvant tamoxifen.
de réir: Davies, C, et al.
Foilsithe / Cruthaithe: (1998)

Multiple Routes to Oestrogen Antagonism
de réir: Hilary R. Glover, et al.
Foilsithe / Cruthaithe: (2010-10-01)

Addition of Adjuvant Tamoxifen to Cyclophosphamide, Methotrexate and 5-Fluorouracil for Premenopausal Women with Oestrogen Receptor-Positive Breast Cancer
de réir: He-Cheng Li, et al.
Foilsithe / Cruthaithe: (2003-07-01)

Oestrogens, brain function and neuropsychiatric disorders
de réir: Craig, M, et al.
Foilsithe / Cruthaithe: (2004)

Influence of the anti‐oestrogens tamoxifen and letrozole on thyroid function in women with early and advanced breast cancer: A systematic review
de réir: Djordje Marina, et al.
Foilsithe / Cruthaithe: (2023-01-01)

Structural insights into the mechanisms of agonism and antagonism in oestrogen receptor isoforms.
de réir: Hubbard, R, et al.
Foilsithe / Cruthaithe: (2000)

Early breast cancer: How long should tamoxifen continue?
de réir: Davies, C, et al.
Foilsithe / Cruthaithe: (1999)

Oestrogen: brain ageing, cognition and neuropsychiatric disorder.
de réir: Norbury, R, et al.
Foilsithe / Cruthaithe: (2004)

[Duration of adjuvant treatment with tamoxifen in patients with resectable breast cancer]
de réir: Davies, C, et al.
Foilsithe / Cruthaithe: (1998)

Tamoxifen therapy for patients with breast cancer - Authors' reply.
de réir: Davies, C, et al.
Foilsithe / Cruthaithe: (2013)

Molecular basis of agonism and antagonism in the oestrogen receptor.
de réir: Brzozowski, A, et al.
Foilsithe / Cruthaithe: (1997)

Structure and mechanism of the oestrogen receptor
de réir: Kong, E, et al.
Foilsithe / Cruthaithe: (2003)

Structure and mechanism of the oestrogen receptor.
de réir: Kong, E, et al.
Foilsithe / Cruthaithe: (2003)

17β-Hydroxysteroid dehydrogenase type 14 is a predictive marker for tamoxifen response in oestrogen receptor positive breast cancer.
de réir: Tove Sivik, et al.
Foilsithe / Cruthaithe: (2012-01-01)

Oestrogen exposure and breast cancer risk.
de réir: Travis, R, et al.
Foilsithe / Cruthaithe: (2003)

Oestrogen Receptor Positive Metastatic Eccrine Porocarcinoma: A Case Report and Review of Anti-Oestrogen Therapy in Rare Cancers
de réir: Anita J.M. Kalakonda, et al.
Foilsithe / Cruthaithe: (2024-03-01)

The role of oestrogen and oestrogen-calcium axis in endometrial carcinoma
de réir: Jingyi Zhou, et al.
Foilsithe / Cruthaithe: (2024-04-01)

Local Oestrogen for Pelvic Floor Disorders: A Systematic Review.
de réir: M A Weber, et al.
Foilsithe / Cruthaithe: (2015-01-01)

Early breast cancer: How long should tamoxifen continue?
de réir: Davies, C, et al.
Foilsithe / Cruthaithe: (1998)

RISK REDUCTION BY STOPPING SMOKING
de réir: Beral, V, et al.
Foilsithe / Cruthaithe: (2013)

English Stop-Smoking Services: One-Year Outcomes.
de réir: Bauld, L, et al.
Foilsithe / Cruthaithe: (2016)

Oestrogen, brain function, and neuropsychiatric disorders.
de réir: Cutter, W, et al.
Foilsithe / Cruthaithe: (2003)

UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years.
de réir: Peto, R, et al.
Foilsithe / Cruthaithe: (2000)

Topical oestrogen keratinises the human foreskin and may help prevent HIV infection.
de réir: Andrew J Pask, et al.
Foilsithe / Cruthaithe: (2008-01-01)

A prospective study of urinary oestrogen excretion and breast cancer risk.
de réir: Key, T, et al.
Foilsithe / Cruthaithe: (1996)

The role of oestrogen therapy in reducing risk of Alzheimer's disease: systematic review
de réir: Gary R. M. Wong, et al.
Foilsithe / Cruthaithe: (2023-11-01)

Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation
de réir: Pascal Gellert, et al.
Foilsithe / Cruthaithe: (2016-11-01)

Modulation of immune functions by oestrogens. Part I
de réir: Jacek R. Wilczyński
Foilsithe / Cruthaithe: (2010-04-01)

Modulation of immune functions by oestrogens. Part II
de réir: Jacek R. Wilczyński
Foilsithe / Cruthaithe: (2010-06-01)

The relationships of SHBG with current and previous use of oral contraceptives and oestrogen replacement therapy.
de réir: Key, T, et al.
Foilsithe / Cruthaithe: (1989)